share_log

JP Morgan Maintains Overweight on Day One Biopharmaceutical, Raises Price Target to $36

Moomoo 24/7 ·  Apr 22 10:30

JP Morgan analyst Anupam Rama maintains Day One Biopharmaceutical (NASDAQ:DAWN) with a Overweight and raises the price target from $32 to $36.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment